Scott P. Myrand

828 total citations
29 papers, 706 citations indexed

About

Scott P. Myrand is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Scott P. Myrand has authored 29 papers receiving a total of 706 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in Scott P. Myrand's work include Lung Cancer Treatments and Mutations (9 papers), Colorectal Cancer Treatments and Studies (5 papers) and Advanced Breast Cancer Therapies (4 papers). Scott P. Myrand is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Colorectal Cancer Treatments and Studies (5 papers) and Advanced Breast Cancer Therapies (4 papers). Scott P. Myrand collaborates with scholars based in United States, United Kingdom and Germany. Scott P. Myrand's co-authors include John J. Reiners, David T. Dudley, M. R. Bleavins, Felix A. de la Iglesia, Michael Shi, J. Christopher States, Cornelis J. Elferink, Tuan S. Nguyen, Sara M. Tolaney and J. Andrew Williams and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Scott P. Myrand

29 papers receiving 699 citations

Peers

Countries citing papers authored by Scott P. Myrand

Since Specialization

Citations

This map shows the geographic impact of Scott P. Myrand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott P. Myrand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott P. Myrand more than expected).

Fields of papers citing papers by Scott P. Myrand

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott P. Myrand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott P. Myrand. The network helps show where Scott P. Myrand may publish in the future.

Co-authorship network of co-authors of Scott P. Myrand

This figure shows the co-authorship network connecting the top 25 collaborators of Scott P. Myrand. A scholar is included among the top collaborators of Scott P. Myrand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott P. Myrand. Scott P. Myrand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer 2016 ·Investigational New Drugs ·Giorgio V. Scagliotti, Jin Hyoung Kang, David C. Smith, Richard K. Rosenberg, Keunchil Park, Sang-We Kim, Wu‐Chou Su, Thomas E. Boyd, Donald Richards, Silvia Novello, Scott M. Hynes, Scott P. Myrand, Ji Lin, Emily Nash Smyth, Sameera R. Wijayawardana, Aimee Bence Lin, Mary Pinder-Schenck	55
2	Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors 2015 ·Investigational New Drugs ·Sandrine Faivre, Anthony J. Olszanski, K. Weigang-Köhler, Hanno Riess, Roger B. Cohen, Xuejing Wang, Scott P. Myrand, Enaksha Wickremsinhe, Candice L. Horn, Haojun Ouyang, Sophie Callies, Karim A. Benhadji, Éric Raymond	11
3	Association between Gene Expression Profiles and Clinical Outcome of Pemetrexed-Based Treatment in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: Exploratory Results from a Phase II Study 2014 ·PLoS ONE ·Dean A. Fennell, Scott P. Myrand, Tuan S. Nguyen, David Ferry, Keith M. Kerr, Perry Maxwell, Stephen D. Moore, Carla Visseren‐Grul, Mayukh Das, M. Nicolson	9
4	Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer. 2014 ·Journal of Clinical Oncology ·Jonathan W. Goldman, Leena Gandhi, Amita Patnaik, Lee S. Rosen, John Hilton, Kyriakos P. Papadopoulos, Sara M. Tolaney, Muralidhar Beeram, Drew Rasco, Scott P. Myrand, Richard P. Beckmann, Palaniappan Kulanthaivel, Martin Frenzel, Damien M. Cronier, Edward M. Chan, Keith T. Flaherty, Patrick Y. Wen, Anthony W. Tolcher, Geoffrey I. Shapiro	26
5	Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer 2013 ·Lung Cancer ·Gerald Schmid‐Bindert, Vittorio Gebbia, Frank Mayer, Edurne Arriola, Diego Márquez-Medina, Kostas Syrigos, Bonne Biesma, Monika I. Leschinger, Bente Frimodt‐Moller, Veronique Ripoche, Scott P. Myrand, Tuan S. Nguyen, Rebecca R. Hozak, Annamaria H. Zimmermann, Carla Visseren‐Grul, Wolfgang Schuette	8
6	Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non–Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial 2013 ·Journal of Thoracic Oncology ·M. Nicolson, Dean A. Fennell, David Ferry, Kenneth J. O’Byrne, Riyaz Shah, Vanessa Potter, G. Skailes, Sunil Upadhyay, Paul Taylor, Valérie André, Tuan S. Nguyen, Scott P. Myrand, Carla Visseren‐Grul, Mayukh Das, Keith M. Kerr	49
7	Translational research (TR) results from pointbreak: A randomized, open-label, phase III study of pemetrexed (Pem)+carboplatin (Cb)+bevacizumab (Bev) followed by maintenance pem+bev (Pem Arm) versus paclitaxel (Pac)+cb+bev followed by maintenance bev (Pac Arm) in patients (pts) with stage IIIB or IV nonsquamous non-small cell lung cancer (ns-NSCLC). 2013 ·Journal of Clinical Oncology ·Edward B. Garon, Jyoti D. Patel, Scott P. Myrand, Tuan S. Nguyen, Craig H. Reynolds, David R. Spigel, Robert C. Hermann, Jingyi Liu, Susan C. Guba, Ramaswamy Govindan, Mark A. Socinski, Philip Bonomi	2
8	Randomized, Phase II, Placebo-Controlled, Double-Blind Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin As First-Line Treatment Followed by Maintenance Treatment in Advanced Ovarian Cancer 2013 ·Journal of Clinical Oncology ·Ignace Vergote, Radoslav Chekerov, Frédéric Amant, Philipp Harter, Antonio Casado, Janusz Emerich, Thomas Bauknecht, (unknown), Scott P. Myrand, Tuan S. Nguyen, Peipei Shi, Jalid Sehouli	18
9	Phase II Study of Enzastaurin in Patients with Follicular Lymphoma: Updated Final Clinical Results and Immunohistochemical Correlations 2012 ·Blood ·Lee S. Schwartzberg, Róbert Hermann, Ian W. Flinn, (unknown), Eric D. Hsi, Oday Hamid, Scott P. Myrand, Boris K. Lin, Donald Thornton, Peipei Shi, Tuan S. Nguyen, Martin Dreyling	4
10	A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma 2011 ·American Journal of Hematology ·Irene M. Ghobrial, Nikhil C. Munshi, Brianna Harris, Peipei Shi, (unknown), Robert Schlossman, Jacob P. Laubach, Kenneth C. Anderson, D. Desaiah, Scott P. Myrand, James E. Wooldridge, Paul G. Richardson, Rafat Abonour	19
11	A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma 2010 ·Anti-Cancer Drugs ·Jen‐Shi Chen, Yee Chao, Yung‐Jue Bang, Enrique Roca, Hyun Cheol Chung, (unknown), Yeul Hong Kim, Scott P. Myrand, Brian P. Mullaney, (unknown), Carlos Linn	17
12	Abstract #LB-256: Enzastaurin inhibits in vivo GSK3\#946; phosphorylation in early breast cancer 2009 ·Cancer Research ·Antonio Llombart‐Cussac, (unknown), (unknown), Sonia Del Barco Berrón, (unknown), (unknown), Gopinath Ganji, (unknown), (unknown), Eva Carrasco, Oluwatoyin Shonukan, Scott P. Myrand, Luna Musib, Brian P. Mullaney, Rámón Colomer	2
13	Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: Results of a Phase II, randomized, noncomparative study 2009 ·Investigational New Drugs ·Donald Richards, (unknown), Carlos Becerra, Lalan S. Wilfong, Robert H. Gersh, Kristi A. Boehm, Zhan Feng, Lina Asmar, Scott P. Myrand, Rebecca R. Hozak, Luping Zhao, John F. Gill, Brian P. Mullaney, Coleman K. Obasaju, Steven J. Nicol	43
14	Limited influence of UGT1A128* and no effect of UGT2B72* polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes 2007 ·British Journal of Clinical Pharmacology ·Vincent Peterkin, Jonathan Bauman, Theunis C. Goosen, (unknown), Michael Man, Joseph Paulauskis, J. Andrew Williams, Scott P. Myrand	46
15	Genotyping for Functionally Important Human CYP2D64 (B) Mutation Using TaqMan Probes 2003 ·Humana Press eBooks ·Michael Shi, Scott P. Myrand, Michael R. Bleavins, Felix A. de la Iglesia	2
16	Differential induction ofCyp1a1,Cyp1b1,Ahd4, andNmo1 in murine skin tumors and adjacent normal epidermis by ligands of the Aryl hydrocarbon receptor 1998 ·Molecular Carcinogenesis ·John J. Reiners, Carol Jones, Nancy J. Hong, Scott P. Myrand	22
17	PD98059 Is an Equipotent Antagonist of the Aryl Hydrocarbon Receptor and Inhibitor of Mitogen-Activated Protein Kinase Kinase 1998 ·Molecular Pharmacology ·John J. Reiners, (unknown), (unknown), David T. Dudley, Scott P. Myrand	135
18	Stable transformation of xeroderma pigmentosum group A cells with an XPA minigene restores normal DNA repair and mutagenesis ofUV-treated plasmids 1996 ·Carcinogenesis ·Scott P. Myrand, Robert S. Topping, J. Christopher States	9
19	Splice site mutations in a xeroderma pigmentosum group A patient with delayed onset of neurological disease 1996 ·Mutation Research/DNA Repair ·J. Christopher States, Scott P. Myrand	12
20	Characterization of the human XPA promoter 1995 ·Gene ·Robert S. Topping, Scott P. Myrand, Brandi L. Williams, Jörg Albert, J. Christopher States	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact